KPT-9274 clinical trials
Also written KPT-9274.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses KPT-9274 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
University of Colorado, Denver (1) · Karyopharm Therapeutics Inc (1) · Antengene Therapeutics Limited (1)
Studies
Open first, then newest update. How each study uses KPT-9274 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid LeukemiaCompletedPhase 1University of Colorado, DenverNCT04914845Written as KPT-9274How we know
- PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)TerminatedPhase 1Karyopharm Therapeutics IncNCT02702492Written as KPT-9274How we know
- A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedPhase 1Antengene Therapeutics LimitedNCT04281420Written as ATG-019How we know